Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
Inducing senescence in cancer cells is emerging as a new therapeutic strategy. In order to find ways to enhance senescence induction by palbociclib, a CDK4/6 inhibitor approved for treatment of metastatic breast cancer, we performed functional genetic screens in palbociclib-resistant cells. Using th...
Main Authors: | Ziva Pogacar, Jackie L Johnson, Lenno Krenning, Giulia De Conti, Fleur Jochems, Cor Lieftink, Arno Velds, Leyma Wardak, Kelvin Groot, Arnout Schepers, Liqin Wang, Ji-Ying Song, Marieke van de Ven, Olaf van Tellingen, Rene H Medema, Roderick L Beijersbergen, Rene Bernards, Rodrigo Leite de Oliveira |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0273182 |
Similar Items
-
The Cancer SENESCopedia: A delineation of cancer cell senescence
by: Fleur Jochems, et al.
Published: (2021-07-01) -
A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
by: Haojie Jin, et al.
Published: (2020-10-01) -
Combined Inactivation of Pocket Proteins and APC/C<sup>Cdh1</sup> by Cdk4/6 Controls Recovery from DNA Damage in G1 Phase
by: Indra A. Shaltiel, et al.
Published: (2021-03-01) -
Hypersensitivity to DNA damage in antephase as a safeguard for genome stability
by: Femke M. Feringa, et al.
Published: (2016-08-01) -
Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
by: Tonći Šuštić, et al.
Published: (2021-02-01)